Regenicin, Inc., is a biotechnology company specializing in the development
of regenerative cell therapies to restore the health of damaged tissues and organs.
Regenicin is playing a critical role in the development of the therapeutic candidate, NovaDerm™, a cultured cell technology that uses the patient’s own skin cells to generate living, tissue-engineered skin for the treatment of severe burns. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days.
January 18, 2017: Regenicin Reports 2016 Operating Results.
click to read artictle
November 17, 2016: Regenicin Signs Supplier Agreement with Pure Med Farma LLC to Provide Closed Herd Collagen for the Manufacturing of NovaDerm®. click to read artictle
November 1, 2016: Regenicin, Inc. Completes Successful Pre-IND Meeting with Food and Drug Administration (FDA) for its New Autologous Cultured Skin Substitute, NovaDerm® . click to read artictle